Abeona Therapeutics (ABEO) PT Set at $36.00 by Cantor Fitzgerald
Abeona Therapeutics (NASDAQ:ABEO) has been assigned a $36.00 price target by stock analysts at Cantor Fitzgerald in a research report issued on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 128.57% from the stock’s previous close.
Several other equities analysts have also weighed in on the company. Royal Bank of Canada reissued a “buy” rating and set a $26.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, January 24th. Maxim Group reissued a “buy” rating and set a $35.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, February 7th. HC Wainwright set a $30.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a report on Thursday, January 4th. Zacks Investment Research lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. Finally, BidaskClub downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $27.33.
Abeona Therapeutics (NASDAQ:ABEO) opened at $15.75 on Tuesday. Abeona Therapeutics has a twelve month low of $4.55 and a twelve month high of $22.75. The firm has a market capitalization of $660.00, a price-to-earnings ratio of -23.86 and a beta of 1.30.
Large investors have recently bought and sold shares of the business. Teacher Retirement System of Texas purchased a new stake in shares of Abeona Therapeutics during the fourth quarter worth $163,000. MetLife Investment Advisors LLC purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth $194,000. SG Americas Securities LLC purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth $218,000. Virtu Financial LLC purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth $246,000. Finally, California State Teachers Retirement System purchased a new stake in shares of Abeona Therapeutics in the second quarter worth $275,000. Hedge funds and other institutional investors own 62.64% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.